AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9540312 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental version of All‐Bond 2 with no water in primer A
Number of subjects: 36
Study 9540312 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial version of All‐Bond 2 (Bisco, Itasca, IL, USA) with 5% water in primer A
Number of subjects: 36
Study 9540312 — intervention group
Group type: EXPERIMENTAL
Intervention: Former version of All‐Bond 2 with 17% water in primer A
Number of subjects: 36
Study 8087502 — intervention group
Group type: EXPERIMENTAL
Intervention: Meta-analyses of randomized trials
Number of subjects: 0
Study 8087502 — intervention group
Group type: EXPERIMENTAL
Intervention: Registry of randomized trials
Number of subjects: 0
Study 8087502 — intervention group
Group type: EXPERIMENTAL
Intervention: Meta-analyses based on individual data
Number of subjects: 0
Study 8087502 — intervention group
Group type: EXPERIMENTAL
Intervention: Collecting and conserving relevant data on ongoing trials
Number of subjects: 0
Study 2643534 — intervention group
Group type: COMPARATOR
Intervention: ET after 48 to 52 hours (day 2)
Number of subjects: 758
Study 2643534 — intervention group
Group type: EXPERIMENTAL
Intervention: ET after 72 to 76 hours (day 3)
Number of subjects: 758
Study 5078403 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloramphenicol combined with ampicillin
Number of subjects: 100
Study 5078403 — intervention group
Group type: COMPARATOR
Intervention: Chloramphenicol
Number of subjects: 100
Study 6101550 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviour Therapy Programme (BTP)
Number of subjects: 23
Study 6101550 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Methadone Withdrawal Programme and Behaviour Therapy Programme (MBT)
Number of subjects: 23
Study 6101550 — intervention group
Group type: COMPARATOR
Intervention: Methadone Withdrawal Programme (MWP)
Number of subjects: 23
Study 6101550 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 23
Study 31750110 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic scalpel (HS)
Number of subjects: 128
Study 31750110 — intervention group
Group type: COMPARATOR
Intervention: Coblation
Number of subjects: 128
Study 29021336 — intervention group
Group type: EXPERIMENTAL
Intervention: RAASi (renin-angiotensin-aldosterone system inhibitors)
Number of subjects: 395
Study 29021336 — intervention group
Group type: EXPERIMENTAL
Intervention: RAASi (within the same class)
Number of subjects: 395
Study 29021336 — intervention group
Group type: EXPERIMENTAL
Intervention: RAASi to NSAIDs
Number of subjects: 395
Study 29021336 — intervention group
Group type: EXPERIMENTAL
Intervention: High to low sodium intake
Number of subjects: 395
Study 26843962 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive therapy group (ITG) with target HbA1c <6.2%, BP <120/75 mm Hg, LDL <80 mg/dL
Number of subjects: 2542
Study 26843962 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy group (CTG) with target HbA1c <6.9%, BP <130/80 mm Hg, LDL <120 mg/dL
Number of subjects: 2542
Study 24704117 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulkamid (polyacrylamide hydrogel)
Number of subjects: 345
Study 24704117 — intervention group
Group type: COMPARATOR
Intervention: Contigen (collagen gel)
Number of subjects: 345
Study 22213250 — intervention group
Group type: EXPERIMENTAL
Intervention: HT1001
Number of subjects: 64
Study 22213250 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 19281474 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan
Number of subjects: 2
Study 19281474 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 17313271 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 19
Study 17313271 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 19
Study 15449696 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive behavior recall
Number of subjects: 0
Study 15449696 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative behavior recall
Number of subjects: 0
Study 11268708 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcichew D3 Forte (CDF)
Number of subjects: 102
Study 11268708 — intervention group
Group type: COMPARATOR
Intervention: Ad Cal D3 (ACD)
Number of subjects: 102
Study 9741406 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular blocking agents (NMBA) and steroids
Number of subjects: 62
Study 9741406 — intervention group
Group type: COMPARATOR
Intervention: Phrenic nerve conduction studies and diaphragmatic EMG
Number of subjects: 62
Study 9741406 — intervention group
Group type: COMPARATOR
Intervention: Limb motor and sensory nerve conductions
Number of subjects: 62
Study 9741406 — intervention group
Group type: COMPARATOR
Intervention: Muscle biopsy findings
Number of subjects: 62
Study 7993512 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal prostaglandin E2 gel
Number of subjects: 20
Study 7993512 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracervical prostaglandin E2 gel
Number of subjects: 20
Study 7993512 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention mentioned)
Number of subjects: 20
Study 3050336 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical fusidic acid 2% cream
Number of subjects: 40
Study 3050336 — intervention group
Group type: COMPARATOR
Intervention: Oral dicloxacillin 500 mg twice a day
Number of subjects: 40
Study 30680633 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise program (aerobic and resistance exercises) for 60 min per day, 3 days per week for 6 weeks
Number of subjects: 19
Study 30680633 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 19
Study 28662232 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (3 mg/kg every 2 weeks) administered until progression or unacceptable toxic effects.
Number of subjects: 526
Study 26383208 — intervention group
Group type: EXPERIMENTAL
Intervention: Training based on the Health Belief Model
Number of subjects: 130
Study 26383208 — intervention group
Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 130
Study 22925176 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral iron (ferrous sulphate 200 mg tablets, 60 mg elemental iron, three times a day for 4 weeks)
Number of subjects: 100
Study 22925176 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron sucrose (200 mg in divided doses on alternate days by slow intravenous infusion)
Number of subjects: 100
Study 22925176 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 100
Study 21382893 — intervention group
Group type: EXPERIMENTAL
Intervention: Apical lead position
Number of subjects: 799
Study 21382893 — intervention group
Group type: COMPARATOR
Intervention: Non-apical lead position (basal or midventricular)
Number of subjects: 799
Study 19932356 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 50 microg twice a day
Number of subjects: 87
Study 19932356 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 16632843 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation of the posterior cord
Number of subjects: 369
Study 16632843 — intervention group
Group type: COMPARATOR
Intervention: Stimulation of the lateral cord
Number of subjects: 369
Study 16632843 — intervention group
Group type: COMPARATOR
Intervention: Stimulation of the medial cord
Number of subjects: 369
Study 16632843 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation of more than one cord simultaneously
Number of subjects: 369
Study 15569840 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 2183
Study 15569840 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2183
Study 11717596 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 4312
Study 11717596 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 4312
Study 9741869 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient antimicrobial regimens
Number of subjects: 312
Study 9741869 — intervention group
Group type: COMPARATOR
Intervention: Inpatient antimicrobial regimens
Number of subjects: 312
Study 7518775 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl-aspartyl-glutamate (ZY15106)
Number of subjects: 15
Study 7518775 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 15
Study 2645796 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxepin hydrochloride 150 mg (N = 9)
Number of subjects: 19
Study 2645796 — intervention group
Group type: COMPARATOR
Intervention: Placebo (N = 10)
Number of subjects: 19
Study 1092726 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 64
Study 1092726 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 31746819 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon Eustachian Tuboplasty (BET)
Number of subjects: 30
Study 31746819 — intervention group
Group type: COMPARATOR
Intervention: Balloon Eustachian Tuboplasty with concurrent tympanocentesis
Number of subjects: 30
Study 30427274 — intervention group
Group type: EXPERIMENTAL
Intervention: Plavix (18.75 mg PO q24h for 7 days)
Number of subjects: 4
Study 30427274 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic clopidogrel (18.75 mg PO q24h for 7 days)
Number of subjects: 4
Study 30427274 — intervention group
Group type: COMPARATOR
Intervention: Plavix
Number of subjects: 4
Study 30427274 — intervention group
Group type: COMPARATOR
Intervention: Generic clopidogrel
Number of subjects: 4
Study 28571258 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate loading of implant within two days of insertion
Number of subjects: 20
Study 28571258 — intervention group
Group type: COMPARATOR
Intervention: Delayed loading of implant after three months of insertion
Number of subjects: 20
Study 24983434 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine follow-up appointments
Number of subjects: 24
Study 24983434 — intervention group
Group type: COMPARATOR
Intervention: In-person follow-up visits
Number of subjects: 24
Study 23263240 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sodium diet (300-350 mmol/day)
Number of subjects: 14
Study 23263240 — intervention group
Group type: COMPARATOR
Intervention: Low-sodium diet (20 mmol/day)
Number of subjects: 14
Study 21145244 — intervention group
Group type: EXPERIMENTAL
Intervention: Phrenic nerve infiltration (PNI) with 10 ml of 2% lidocaine
Number of subjects: 74
Study 21145244 — intervention group
Group type: COMPARATOR
Intervention: Suprascapular nerve block (SNB) with 10 ml of 0.5% plain bupivacaine
Number of subjects: 74
Study 21145244 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (PNI and SNB)
Number of subjects: 74
Study 19653086 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate
Number of subjects: 740
Study 17955789 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS hydromorphone once daily
Number of subjects: 0
Study 17955789 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS hydromorphone
Number of subjects: 0
Study 15069400 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (5 mg/d)
Number of subjects: 36
Study 15069400 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 11286448 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole 1g orally, 1 hour preoperatively
Number of subjects: 151
Study 11286448 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole 400mg orally eight hourly for 5 days postoperatively
Number of subjects: 151
Study 11286448 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study 9305320 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolcapone 100 mg three times daily
Number of subjects: 298
Study 9305320 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolcapone 200 mg three times daily
Number of subjects: 298
Study 9305320 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolcapone (both dosages)
Number of subjects: 298
Study 9305320 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 298
Study 8485014 — intervention group
Group type: EXPERIMENTAL
Intervention: TEB (automated transthoracic electrical bioimpedance method)
Number of subjects: 10
Study 8485014 — intervention group
Group type: COMPARATOR
Intervention: ZCG (standard transthoracic impedance cardiography)
Number of subjects: 10
Study 3732372 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed combination of hydrochlorothiazide 25 mg and triamterene 50 mg
Number of subjects: 30
Study 3732372 — intervention group
Group type: COMPARATOR
Intervention: Free combination of furosemide 40 mg and triamterene 50 mg
Number of subjects: 30
Study 29976181 — intervention group
Group type: EXPERIMENTAL
Intervention: Early involvement of the patient's employer in rehabilitation
Number of subjects: 132
Study 29976181 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 132
Study 27502815 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot reflexology
Number of subjects: 105
Study 27502815 — intervention group
Group type: EXPERIMENTAL
Intervention: Back massage
Number of subjects: 105
Study 24760962 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic postconditioning (IPost) administered by 4 cycles of 1-minute reocclusion and 1-minute reperfusion, starting 1 minute after opening, followed by stenting.
Number of subjects: 272
Study 24760962 — intervention group
Group type: COMPARATOR
Intervention: Control group with immediate stenting after reperfusion.
Number of subjects: 272
Study 22301933 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-protein HMF (1.4 g protein/100 mL)
Number of subjects: 92
Study 22301933 — intervention group
Group type: COMPARATOR
Intervention: Standard-protein HMF (1.0 g protein/100 mL)
Number of subjects: 92
Study 20842617 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication adherence during the maintenance phase
Number of subjects: 1831
Study 20842617 — intervention group
Group type: EXPERIMENTAL
Intervention: Insight into illness at week 12
Number of subjects: 1831
Study 20842617 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis abuse/dependence during the acute phase
Number of subjects: 1831
Study 20842617 — intervention group
Group type: EXPERIMENTAL
Intervention: Work impairment
Number of subjects: 1831
Study 20842617 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher CGI hallucinations/delusions at baseline
Number of subjects: 1831
Study 18394319 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP plus 1 CHX chip
Number of subjects: 82
Study 18394319 — intervention group
Group type: COMPARATOR
Intervention: SRP alone
Number of subjects: 82
Study 16170294 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum progesterone (P) levels on the day of human chorionic gonadotropin (hCG) administration
Number of subjects: 460
Study 12429069 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiral-CT screening (A)
Number of subjects: 0
Study 12429069 — intervention group
Group type: EXPERIMENTAL
Intervention: X-ray screening (B)
Number of subjects: 0
Study 12429069 — intervention group
Group type: COMPARATOR
Intervention: No screening (C)
Number of subjects: 0
Study 10490789 — intervention group
Group type: EXPERIMENTAL
Intervention: (‐)‐HCA (3.0 g/d)
Number of subjects: 10
Study 10490789 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 8526959 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous monitoring via pulsoximeter and capnometer
Number of subjects: 30
Study 8526959 — intervention group
Group type: COMPARATOR
Intervention: Regular assessments of respiratory rate and blood gas analysis
Number of subjects: 30
Study 8526959 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled intravenous analgesia with sufentanil (15 micrograms initial bolus)
Number of subjects: 30
Study 1638578 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoxitin (CFX)
Number of subjects: 51
Study 1638578 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin-Clindamycin (G/C)
Number of subjects: 51
Study 6707245 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine
Number of subjects: 20
Study 6707245 — intervention group
Group type: EXPERIMENTAL
Intervention: Thioridazine plus either social skills training or holistic health therapy
Number of subjects: 20
Study 30853647 — intervention group
Group type: EXPERIMENTAL
Intervention: Purgative Manna drops (5 drops/kg divided into three doses per day for three days)
Number of subjects: 445
Study 30853647 — intervention group
Group type: EXPERIMENTAL
Intervention: Purgative Manna drops
Number of subjects: 445
Study 30853647 — intervention group
Group type: COMPARATOR
Intervention: Placebo drops
Number of subjects: 445
Study 29903598 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive functional therapy
Number of subjects: 148
Study 29903598 — intervention group
Group type: COMPARATOR
Intervention: Combined manual therapy and motor control exercises
Number of subjects: 148
Study 27601883 — intervention group
Group type: EXPERIMENTAL
Intervention: Gratisovir (400 mg daily)
Number of subjects: 50
Study 27601883 — intervention group
Group type: COMPARATOR
Intervention: Grateziano (400 mg daily)
Number of subjects: 50
Study 24627237 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 45 mg/m² with bolus and 44 h infusion of 5-Fu/Lv (arm T)
Number of subjects: 81
Study 24627237 — intervention group
Group type: COMPARATOR
Intervention: Irinotecan 180 mg/m² with bolus and 44 h infusion of 5-Fu/Lv (arm C)
Number of subjects: 81
Study 24627237 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens after crossover
Number of subjects: 81
Study 24627237 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy in advanced GC
Number of subjects: 81
Study 22586106 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic variability of the gene encoding PKCα (PRKCA)
Number of subjects: 0
Study 22586106 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional magnetic resonance imaging (fMRI)
Number of subjects: 0
Study 22586106 — intervention group
Group type: EXPERIMENTAL
Intervention: Identified genetic variant
Number of subjects: 0
Study 19680704 — intervention group
Group type: EXPERIMENTAL
Intervention: Lupin protein
Number of subjects: 43
Study 19680704 — intervention group
Group type: COMPARATOR
Intervention: Casein (control)
Number of subjects: 43
Study 19680704 — intervention group
Group type: COMPARATOR
Intervention: Lupin protein vs Casein
Number of subjects: 43
Study 19062728 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid combined with local radiotherapy
Number of subjects: 45
Study 19062728 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 45
Study 15695781 — intervention group
Group type: EXPERIMENTAL
Intervention: (18)F-FDG PET imaging in patients with FTD
Number of subjects: 29
Study 14660711 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (ACZ) administration
Number of subjects: 22
Study 10469748 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral prophylactic oophorectomy
Number of subjects: 122
Study 8782340 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine
Number of subjects: 1136
Study 8782340 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Number of subjects: 1136
Study 8782340 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccine
Number of subjects: 1136
Study 8782340 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1136
Study 8782340 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall and arm size data
Number of subjects: 1136
Study 1723463 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine
Number of subjects: 40
Study 6192505 — intervention group
Group type: EXPERIMENTAL
Intervention: Tendamistate 100 mg
Number of subjects: 6
Study 6192505 — intervention group
Group type: EXPERIMENTAL
Intervention: Tendamistate 200 mg
Number of subjects: 6
Study 6192505 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31962191 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot strengthening program (IG)
Number of subjects: 28
Study 31962191 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 28
Study 31649125 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous microtracer of 10 µg [14C]nemiralisib
Number of subjects: 6
Study 31649125 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nonradiolabeled 1000 µg dose
Number of subjects: 6
Study 31649125 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 800 µg dose of [14C]nemiralisib
Number of subjects: 6
Study 27612466 — intervention group
Group type: EXPERIMENTAL
Intervention: B group vitamin
Number of subjects: 71
Study 25395210 — intervention group
Group type: EXPERIMENTAL
Intervention: NSC 631570 administered i.v. in a single therapeutic dose
Number of subjects: 8
Study 25395210 — intervention group
Group type: EXPERIMENTAL
Intervention: NSC 631570 administered i.v. in an outpatient setting
Number of subjects: 8
Study 25395210 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate physical exercise (50 slow squats)
Number of subjects: 8
Study 25395210 — intervention group
Group type: EXPERIMENTAL
Intervention: NSC 631570 administered in an inpatient setting
Number of subjects: 8
Study 25395210 — intervention group
Group type: EXPERIMENTAL
Intervention: Active participants after drug injection
Number of subjects: 8
Study 24421054 — intervention group
Group type: EXPERIMENTAL
Intervention: β‐glucan 10 mg capsules administered twice a day for 10 days
Number of subjects: 130
Study 24421054 — intervention group
Group type: EXPERIMENTAL
Intervention: β‐glucan
Number of subjects: 130
Study 24421054 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 21822034 — intervention group
Group type: EXPERIMENTAL
Intervention: Juice Plus+® (micronutrient concentrate)
Number of subjects: 26
Study 21822034 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 19144772 — intervention group
Group type: EXPERIMENTAL
Intervention: CRA13 1-80 mg
Number of subjects: 63
Study 19144772 — intervention group
Group type: EXPERIMENTAL
Intervention: CRA13 40 mg with food
Number of subjects: 63
Study 19144772 — intervention group
Group type: EXPERIMENTAL
Intervention: CRA13 40-80 mg
Number of subjects: 63
Study 19144772 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 17615477 — intervention group
Group type: EXPERIMENTAL
Intervention: Oropharyngeal sensory stimulation for 1020 minutes, 1 time per day for 2 weeks
Number of subjects: 32